本文選題：貝伐單抗 + 順鉑��； 參考：《中國臨床藥理學(xué)雜志》2017年23期

【摘要】：目的探討貝伐單抗聯(lián)合順鉑對Lewis肺癌荷瘤小鼠免疫功能及血管內(nèi)皮生長因子(VEGF)的影響。方法對SBF級健康BALB/c裸鼠右腋下注射處于對數(shù)生長期鼠源性Lewis肺癌細(xì)胞,建立肺癌小鼠模型。將造模成功的小鼠隨機分為模型組、實驗A組、實驗B組和實驗C組,每組8只;另取8只健康裸鼠作為對照組。模型組和對照組均給予腹腔注射0.9%Na Cl 0.4 m L,每周2次;實驗A組給予腹腔注射15 mg·kg~(-1)貝伐單抗,每周2次;實驗B組給予腹腔注射5 mg·kg~(-1)順鉑,每周2次;實驗C組給予腹腔注射15 mg·kg~(-1)貝伐單抗和5 mg·kg~(-1)順鉑,每周2次。5組裸鼠均連續(xù)給藥2周后處死,摘眼球取血和取瘤稱重。比較5組裸鼠的抵瘤率、免疫功能、VEGF水平。結(jié)果治療后,實驗A,B,C組的抑瘤率分別為(46.57±5.45)%,(72.03±8.24)%和(87.47±9.02)%,任意2組比較,差異均有統(tǒng)計學(xué)意義(均P0.05)。治療后,對照組、模型組和實驗A,B,C組的白細(xì)胞介素-2水平分別為(37.12±5.24),(15.24±2.36),(26.45±4.45),(7.36±1.02)和(22.32±3.25)pg·m L-1,白細(xì)胞介素-6水平分別為(125.36±15.24),(54.32±6.32),(86.45±10.12),(24.36±3.45)和(74.36±8.54)pg·m L-1,腫瘤壞死因子-α水平分別為(80.12±4.25),(32.45±4.56),(62.54±7.24),(17.36±2.54)和(52.12±6.35)pg·m L-1,CD3+分別為(66.45±6.74)%,(38.52±4.56)%,(50.32±5.23)%,(21.32±3.24)%和(44.12±4.65)%,CD4+分別為(42.36±5.12)%,(26.02±3.54)%,(34.12±4.21)%,(20.42±3.25)%和(30.25±3.45)%,CD4+/CD8+比率分別為(1.83±0.32),(0.83±0.14),(1.36±0.30),(0.54±0.10)和(1.06±0.22),血清中VEGF分別為(10.42±1.24),(33.45±4.32),(23.36±2.45),(28.12±3.25)和(20.12±2.32)pg·m L-1,腫瘤組織中VEGF分別為(0.21±0.06),(1.04±0.21),(0.51±0.10),(0.76±0.12)和(0.38±0.05)pg·m L-1,實驗A,B,C組的上述指標(biāo)與模型組比較,差異均有統(tǒng)計學(xué)意義(均P0.05);實驗B,C組的上述指標(biāo)與實驗A組比較,差異均有統(tǒng)計學(xué)意義(均P0.05);實驗B組的上述指標(biāo)和實驗C組比較,差異均有統(tǒng)計學(xué)意義(均P0.05)。結(jié)論貝伐單抗聯(lián)合順鉑有助于抑制Lewis肺癌荷瘤小鼠瘤體生長,可能與其能夠改善免疫功能、降低血管內(nèi)皮生長因子含量等因素有關(guān)。
[Abstract]:Objective to investigate the effect of bevacizumab combined with cisplatin on immune function and vascular endothelial growth factor (VEGF) in Lewis lung cancer bearing mice. Methods the right subaxillary injection of murine Lewis lung cancer cells at logarithmic growth stage in SBF grade BALB / c nude mice was used to establish lung cancer model in mice. The mice were randomly divided into three groups: model group, experimental group A, experimental group B and experimental group C with 8 mice in each group, and 8 healthy nude mice as control group. The model group and control group were given intraperitoneal injection of 0.9% NaCl 0.4 mL twice a week, group A received intraperitoneal injection of 15 mg 路kg ~ (-1) bevacizumab twice a week, group B received intraperitoneal injection of 5 mg 路kg ~ (-1) cisplatin twice a week. Group C was given intraperitoneal injection of 15 mg 路kg ~ (-1) bevacizumab and 5 mg 路kg ~ (-1) 路kg ~ (-1) of cisplatin. The nude mice in group 5 were sacrificed after 2 weeks of continuous administration, and blood and tumor were removed and weighed. The tumor arrival rate and the level of VEGF in immune function were compared in 5 groups of nude mice. Results after treatment, the tumor inhibition rates of the experimental group A (46.57 鹵5.45) were 72.03 鹵8.24% and 87.47 鹵9.02%, respectively. The difference between any two groups was statistically significant (all P 0.05). After treatment, the control group, 妯″瀷緇勫拰瀹為獙A,B,C緇勭殑鐧界粏鑳?yōu)浠嬬矗?

本文編號：2031934